Published in Glycobiology on March 10, 2008
Glycomics and disease markers. Curr Opin Chem Biol (2009) 2.04
The prevalence and nature of glycan alterations on specific proteins in pancreatic cancer patients revealed using antibody-lectin sandwich arrays. Mol Cell Proteomics (2009) 1.77
Aberrant glycosylation associated with enzymes as cancer biomarkers. Clin Proteomics (2011) 1.36
High-sensitivity analytical approaches for the structural characterization of glycoproteins. Chem Rev (2013) 1.23
Clustered O-glycans of IgA1: defining macro- and microheterogeneity by use of electron capture/transfer dissociation. Mol Cell Proteomics (2010) 1.21
Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis. Breast Cancer Res (2011) 1.20
Over-expression of ST3Gal-I promotes mammary tumorigenesis. Glycobiology (2010) 1.14
Two opposing roles of O-glycans in tumor metastasis. Trends Mol Med (2012) 0.99
Aberrant O-glycosylation and anti-glycan antibodies in an autoimmune disease IgA nephropathy and breast adenocarcinoma. Cell Mol Life Sci (2012) 0.89
Expression of underglycosylated MUC1 antigen in cancerous and adjacent normal breast tissues. Clin Breast Cancer (2012) 0.89
Protein modifications as potential biomarkers in breast cancer. Biomark Insights (2009) 0.87
Evaluation of riproximin binding properties reveals a novel mechanism for cellular targeting. J Biol Chem (2012) 0.83
Exploring the glycosylation of serum CA125. Int J Mol Sci (2013) 0.82
Enzymatic sialylation of IgA1 O-glycans: implications for studies of IgA nephropathy. PLoS One (2014) 0.82
Sequential two-step multienzyme synthesis of tumor-associated sialyl T-antigens and derivatives. Org Biomol Chem (2011) 0.82
Overexpression of α2,3sialyl T-antigen in breast cancer determined by miniaturized glycosyltransferase assays and confirmed using tissue microarray immunohistochemical analysis. Glycoconj J (2014) 0.80
One-pot multi-enzyme (OPME) chemoenzymatic synthesis of sialyl-Tn-MUC1 and sialyl-T-MUC1 glycopeptides containing natural or non-natural sialic acid. Bioorg Med Chem (2013) 0.80
Onco-Golgi: Is Fragmentation a Gate to Cancer Progression? Biochem Mol Biol J (2015) 0.80
Characterization of cancer associated mucin type O-glycans using the exchange sialylation properties of mammalian sialyltransferase ST3Gal-II. J Proteome Res (2012) 0.79
Glycosylation-Based Serum Biomarkers for Cancer Diagnostics and Prognostics. Biomed Res Int (2015) 0.77
Synthesis and cell-selective antitumor properties of amino acid conjugated tumor-associated carbohydrate antigen-coated gold nanoparticles. Carbohydr Res (2014) 0.76
A HPLC-based glycoanalytical protocol allows the use of natural O-glycans derived from glycoproteins as substrates for glycosidase discovery from microbial culture. Glycoconj J (2013) 0.76
Glycans in sera of amyotrophic lateral sclerosis patients and their role in killing neuronal cells. PLoS One (2012) 0.76
CNS active O-linked glycopeptides. Front Chem (2015) 0.76
Serum glycoprotein-derived N- and O-linked glycans as cancer biomarkers. Am J Cancer Res (2016) 0.75
Structures and binding specificity of galactose- and mannose-binding lectins from champedak: differences from jackfruit lectins. Acta Crystallogr F Struct Biol Commun (2014) 0.75
Assessment of tumor characteristics based on glycoform analysis of membrane-tethered MUC1. Lab Invest (2017) 0.75
The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120. J Virol (2002) 7.82
Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science (2003) 6.68
Prognostic markers in triple-negative breast cancer. Cancer (2007) 6.28
The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol (2007) 4.96
Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol (2002) 3.53
Statistical analysis of the protein environment of N-glycosylation sites: implications for occupancy, structure, and folding. Glycobiology (2003) 3.19
Exploiting the defensive sugars of HIV-1 for drug and vaccine design. Nature (2007) 3.01
Proposal for a standard system for drawing structural diagrams of N- and O-linked carbohydrates and related compounds. Proteomics (2009) 2.93
Comparison of the methods for profiling glycoprotein glycans--HUPO Human Disease Glycomics/Proteome Initiative multi-institutional study. Glycobiology (2007) 2.71
Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. Proc Natl Acad Sci U S A (2005) 2.70
The hepatitis C virus p7 protein forms an ion channel that is inhibited by long-alkyl-chain iminosugar derivatives. Proc Natl Acad Sci U S A (2003) 2.64
Structural characterization of the 1918 influenza virus H1N1 neuraminidase. J Virol (2008) 2.63
Stem cells act through multiple mechanisms to benefit mice with neurodegenerative metabolic disease. Nat Med (2007) 2.57
Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens. Proc Natl Acad Sci U S A (2010) 2.51
Infantile-onset symptomatic epilepsy syndrome caused by a homozygous loss-of-function mutation of GM3 synthase. Nat Genet (2004) 2.45
Ovarian cancer is associated with changes in glycosylation in both acute-phase proteins and IgG. Glycobiology (2007) 2.45
Glycoprotein structural genomics: solving the glycosylation problem. Structure (2007) 2.40
Variability, heritability and environmental determinants of human plasma N-glycome. J Proteome Res (2009) 2.39
A systematic approach to protein glycosylation analysis: a path through the maze. Nat Chem Biol (2010) 2.30
Contrasting IgG structures reveal extreme asymmetry and flexibility. J Mol Biol (2002) 2.10
The mannose receptor mediates dengue virus infection of macrophages. PLoS Pathog (2008) 2.09
Conformational studies of oligosaccharides and glycopeptides: complementarity of NMR, X-ray crystallography, and molecular modelling. Chem Rev (2002) 2.02
The glycan shield of HIV is predominantly oligomannose independently of production system or viral clade. PLoS One (2011) 1.95
Evaluation of the serum N-linked glycome for the diagnosis of cancer and chronic inflammation. Proteomics (2008) 1.94
HPLC-based analysis of serum N-glycans on a 96-well plate platform with dedicated database software. Anal Biochem (2007) 1.92
Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins. Glycobiology (2003) 1.91
Reversible infertility in male mice after oral administration of alkylated imino sugars: a nonhormonal approach to male contraception. Proc Natl Acad Sci U S A (2002) 1.88
Implications for invariant natural killer T cell ligands due to the restricted presence of isoglobotrihexosylceramide in mammals. Proc Natl Acad Sci U S A (2007) 1.84
Emerging principles for the therapeutic exploitation of glycosylation. Science (2014) 1.83
Antiviral effects of an iminosugar derivative on flavivirus infections. J Virol (2002) 1.80
Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur J Cancer (2006) 1.76
High throughput isolation and glycosylation analysis of IgG-variability and heritability of the IgG glycome in three isolated human populations. Mol Cell Proteomics (2011) 1.70
Secretory IgA N- and O-glycans provide a link between the innate and adaptive immune systems. J Biol Chem (2003) 1.68
Glycans as cancer biomarkers. Biochim Biophys Acta (2011) 1.66
EarlyCDT-Lung: an immunobiomarker test as an aid to early detection of lung cancer. Cancer Prev Res (Phila) (2011) 1.65
Storage solutions: treating lysosomal disorders of the brain. Nat Rev Neurosci (2005) 1.65
GlycoBase and autoGU: tools for HPLC-based glycan analysis. Bioinformatics (2008) 1.64
Different glycan structures in prostate-specific antigen from prostate cancer sera in relation to seminal plasma PSA. Glycobiology (2005) 1.60
Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients. Clin Cancer Res (2008) 1.58
A strategy to reveal potential glycan markers from serum glycoproteins associated with breast cancer progression. Glycobiology (2008) 1.55
Loci associated with N-glycosylation of human immunoglobulin G show pleiotropy with autoimmune diseases and haematological cancers. PLoS Genet (2013) 1.52
Novel serum biomarker candidates for liver fibrosis in hepatitis C patients. Clin Chem (2007) 1.52
EarlyCDT®-Lung test: improved clinical utility through additional autoantibody assays. Tumour Biol (2012) 1.52
Genes contributing to prion pathogenesis. J Gen Virol (2008) 1.51
Treatment with miglustat reverses the lipid-trafficking defect in Niemann-Pick disease type C. Neurobiol Dis (2004) 1.50
Antiviral effects of amantadine and iminosugar derivatives against hepatitis C virus. Hepatology (2007) 1.49
Structural and quantitative analysis of N-linked glycans by matrix-assisted laser desorption ionization and negative ion nanospray mass spectrometry. Anal Biochem (2008) 1.49
Human serum IgM glycosylation: identification of glycoforms that can bind to mannan-binding lectin. J Biol Chem (2005) 1.47
The 3-dimensional structure of a hepatitis C virus p7 ion channel by electron microscopy. Proc Natl Acad Sci U S A (2009) 1.44
Detailed structural analysis of N-glycans released from glycoproteins in SDS-PAGE gel bands using HPLC combined with exoglycosidase array digestions. Methods Mol Biol (2006) 1.43
Genomics meets glycomics-the first GWAS study of human N-Glycome identifies HNF1α as a master regulator of plasma protein fucosylation. PLoS Genet (2010) 1.43
Analysis of fluorescently labeled glycosphingolipid-derived oligosaccharides following ceramide glycanase digestion and anthranilic acid labeling. Anal Biochem (2004) 1.42
Reactivity-based one-pot synthesis of oligomannoses: defining antigens recognized by 2G12, a broadly neutralizing anti-HIV-1 antibody. Angew Chem Int Ed Engl (2004) 1.41
Inhibition of mammalian glycan biosynthesis produces non-self antigens for a broadly neutralising, HIV-1 specific antibody. J Mol Biol (2007) 1.41
Molecular mechanism of lipopeptide presentation by CD1a. Immunity (2005) 1.41
Polysaccharide mimicry of the epitope of the broadly neutralizing anti-HIV antibody, 2G12, induces enhanced antibody responses to self oligomannose glycans. Glycobiology (2010) 1.39
Differential proteome analysis of TRAP-activated platelets: involvement of DOK-2 and phosphorylation of RGS proteins. Blood (2003) 1.39
Effects of aging, body mass index, plasma lipid profiles, and smoking on human plasma N-glycans. Glycobiology (2010) 1.37
The hemopexin and O-glycosylated domains tune gelatinase B/MMP-9 bioavailability via inhibition and binding to cargo receptors. J Biol Chem (2006) 1.36
Novel glycan biomarkers for the detection of lung cancer. J Proteome Res (2011) 1.33
Increased levels of galactose-deficient anti-Gal immunoglobulin G in the sera of hepatitis C virus-infected individuals with fibrosis and cirrhosis. J Virol (2007) 1.33
Detailed glycan analysis of serum glycoproteins of patients with congenital disorders of glycosylation indicates the specific defective glycan processing step and provides an insight into pathogenesis. Glycobiology (2003) 1.32
Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses. Glycobiology (2005) 1.31
Glycosylation changes on serum glycoproteins in ovarian cancer may contribute to disease pathogenesis. Dis Markers (2008) 1.27